Thompson Investment Management Inc. lifted its stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 4.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 251,955 shares of the medical research company's stock after purchasing an additional 10,181 shares during the period. Exact Sciences comprises about 1.6% of Thompson Investment Management Inc.'s holdings, making the stock its 10th largest holding. Thompson Investment Management Inc. owned about 0.14% of Exact Sciences worth $10,907,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Stratos Wealth Partners LTD. acquired a new stake in shares of Exact Sciences during the fourth quarter worth about $223,000. Kestra Private Wealth Services LLC increased its position in Exact Sciences by 22.9% during the 4th quarter. Kestra Private Wealth Services LLC now owns 8,387 shares of the medical research company's stock worth $471,000 after purchasing an additional 1,564 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in Exact Sciences during the 4th quarter worth approximately $478,000. Vontobel Holding Ltd. boosted its stake in shares of Exact Sciences by 47.0% during the 4th quarter. Vontobel Holding Ltd. now owns 5,833 shares of the medical research company's stock worth $328,000 after acquiring an additional 1,865 shares in the last quarter. Finally, Walkner Condon Financial Advisors LLC boosted its stake in shares of Exact Sciences by 6.7% during the 4th quarter. Walkner Condon Financial Advisors LLC now owns 8,517 shares of the medical research company's stock worth $447,000 after acquiring an additional 534 shares in the last quarter. 88.82% of the stock is currently owned by hedge funds and other institutional investors.
Exact Sciences Stock Down 0.9%
NASDAQ EXAS traded down $0.49 during trading hours on Friday, hitting $53.52. The company had a trading volume of 1,266,159 shares, compared to its average volume of 2,600,440. Exact Sciences Co. has a fifty-two week low of $39.97 and a fifty-two week high of $72.83. The company has a market capitalization of $10.10 billion, a price-to-earnings ratio of -9.61 and a beta of 0.98. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. The firm's 50 day moving average is $50.99 and its 200 day moving average is $52.11.
Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.16. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The firm had revenue of $706.79 million during the quarter, compared to the consensus estimate of $688.58 million. During the same period in the prior year, the firm earned ($0.60) EPS. The firm's quarterly revenue was up 10.9% compared to the same quarter last year. Sell-side analysts anticipate that Exact Sciences Co. will post -0.58 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on EXAS. Evercore ISI upped their target price on Exact Sciences from $60.00 to $66.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Royal Bank of Canada increased their price target on Exact Sciences from $52.00 to $54.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd. Robert W. Baird increased their price target on Exact Sciences from $69.00 to $72.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Scotiabank increased their price target on Exact Sciences from $70.00 to $73.00 and gave the stock a "sector outperform" rating in a research note on Monday, February 24th. Finally, Piper Sandler reduced their price target on Exact Sciences from $75.00 to $70.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $70.90.
Read Our Latest Analysis on Exact Sciences
About Exact Sciences
(
Free Report)
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Featured Articles
Before you consider Exact Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exact Sciences wasn't on the list.
While Exact Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
